

PRESS RELEASE

Global multicenter study: QuickMIC® proven 75% faster in sepsis diagnostics

Uppsala, Sweden, October 16, 2025. **The diagnostics company Gradientech today announces a new scientific publication confirming the QuickMIC® system to deliver accurate antibiotic susceptibility testing (AST) results up to 75% faster than current gold-standards automated solutions, enabling faster treatment decision for sepsis and blood stream infections. The clinical data is published in the high-ranked European Journal of Clinical Microbiology & Infectious Diseases.**

Conducted across four leading hospitals in Europe and the United States, the international multicenter study demonstrates that the QuickMIC ultra-rapid AST system significantly reduces the time needed to deliver actionable results for bloodstream infections, while maintaining high accuracy. The study evaluated 155 patient samples across 10 species of Gram-negative bacteria, comparing the QuickMIC system to three widely used automated AST platforms: BD Phoenix™, MicroScan WalkAway Plus and VITEK® 2. The QuickMIC system demonstrated an essential and categorical agreement of over 95% with the routine systems – a strong indicator of test accuracy.

More strikingly, the average time-to-result (TTR) with QuickMIC was just 3 hours and 4 minutes, compared to 9-19 hours for standard of care systems. This translates to a 53-75% reduction in overall turnaround time (TAT, the total time of the diagnostic workflow from blood culture positivity) – with QuickMIC delivering actionable results in 10-11.5 hours, versus 22-45 hours for current methods.

“This international multicenter study is another brick in building solid proof of the clinical value that QuickMIC brings. By reducing turnaround time by up to 75%, it addresses a critical need in sepsis care - delivering rapid, reliable results when early, targeted therapy can save lives,” says Sara Thorslund, co-founder and CEO at Gradientech.

The study is published in the European Journal of Clinical Microbiology & Infectious Diseases. To access the full article, visit: <https://doi.org/10.1007/s10096-025-05298-z>

QuickMIC® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.